Highlight
- A shorter interval from diagnosis to initiation of immunochemotherapy independently predicts inferior progression-free and overall survival in follicular lymphoma.
- This prognostic value persists beyond established indices such as FLIPI and GELF criteria, suggesting independent biological or clinical significance.
- Findings derive from analysis of large, international discovery and validation patient cohorts, supporting generalizability.
- Results have implications for risk stratification, clinical trial design, and timing of therapy initiation strategies in follicular lymphoma care.
Study Background
Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma, characterized by an indolent clinical course but heterogeneous outcomes. Immunochemotherapy regimens combining anti-CD20 monoclonal antibodies with chemotherapy remain frontline standard treatment for patients requiring therapy. Despite advances, reliable prognostic markers to guide timing and intensity of treatment are limited. Established prognostic tools like the Follicular Lymphoma International Prognostic Index (FLIPI) aid risk stratification but do not incorporate timing factors.
A prevailing clinical question is whether the time elapsed from histopathologic diagnosis to initiation of immunochemotherapy — the diagnosis-to-treatment interval (DTI) — influences patient outcomes independently. This study sought to evaluate the prognostic relevance of DTI in FL treated with immunochemotherapy across large, well-characterized international patient cohorts, bridging a crucial knowledge gap with potential to refine clinical algorithms.
Study Design
This investigation utilized two multinational cohorts to explore DTI as a prognostic variable. The discovery cohort encompassed newly diagnosed FL patients treated with frontline immunochemotherapy, with detailed clinical, biochemical, and treatment data. A validation cohort with comparable inclusion criteria corroborated initial findings.
Exposure of interest was the DTI, defined as the interval (in days) between initial pathological diagnosis and the first administration of immunochemotherapy. Patients were stratified into groups based on short versus long DTI using empirically derived cutoffs optimized for prognostic discrimination.
Primary endpoints evaluated included progression-free survival (PFS) and overall survival (OS). Multivariate Cox regression models adjusted for established prognostic indices (FLIPI score, GELF criteria), patient demographics, and disease characteristics assessed the independent effect of DTI.
Key Findings
Analysis demonstrated that a shorter DTI was significantly associated with inferior PFS and OS in patients receiving immunochemotherapy for FL. This relationship was robust after accounting for standard clinical prognostic factors, including FLIPI and bulk disease criteria, indicating that DTI conveyed additive prognostic information.
Specifically, patients with a diagnosis-to-treatment interval below the defined cutoff had a notably higher risk of early progression and mortality during follow-up. Hazard ratios in multivariable models showed that short DTI remained a strong independent predictor, with confidence intervals excluding null effect.
Secondary analyses exploring potential confounders found no evidence that the association was merely due to aggressive disease phenotype prompting urgent treatment, suggesting that biological or healthcare delivery factors underpin the prognostic significance of DTI.
Importantly, these observations held true across international independent cohorts, reinforcing the reproducibility and generalizability of the findings.
Expert Commentary
This landmark study provides compelling evidence that the interval between diagnosis and treatment initiation is not merely a logistical metric but a clinically meaningful prognostic factor in follicular lymphoma. It challenges the conventional perception that time to treatment initiation is irrelevant in indolent lymphomas and opens avenues for refining patient risk stratification.
From a biological perspective, shorter DTI may reflect intrinsic tumor aggressiveness or host factors accelerating clinical progression, although confounding by indication cannot be entirely excluded. Alternatively, the interval could signal disparities in healthcare access and promptness of therapy delivery, impacting outcomes.
Clinically, integrating DTI assessment into routine prognostic evaluation could optimize therapeutic strategies and patient counseling. It holds particular relevance for designing clinical trials, where balancing DTI across treatment arms might reduce bias and improve interpretation.
Limitations include retrospective cohort design and potential residual confounding by unmeasured variables. Prospective studies should validate these findings and investigate mechanistic underpinnings.
Conclusion
The diagnosis-to-treatment interval emerges as an independent and validated prognostic marker in follicular lymphoma patients undergoing immunochemotherapy, complementing established indices. This novel insight mandates consideration of timing factors during clinical assessment, and further research is warranted to elucidate mechanisms and optimize treatment algorithms. These findings underscore the importance of timely therapeutic initiation while recognizing that overly expedited treatment does not guarantee better outcomes.
Funding and Clinical Trials
The study was supported by multinational collaborative institutions and funding agencies involved in lymphoma research. Specific clinical trial registration numbers were not provided in the publication abstract.
References
1. Vodička P, El-Galaly TC, Procházka V, et al. Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy. Blood. 2026 Jun 25;147(26):3248-3252. PMID: 41980013.
2. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-65.
3. Federico M, Luminari S, Dondi A, et al. High tumor burden in follicular lymphoma in the era of PET and rituximab. Blood. 2013;122(17):2914-20.
4. Casulo C, Friedberg JW. Decision-Making in Follicular Lymphoma: Balancing the Need for Treatment Initiation. Hematology Am Soc Hematol Educ Program. 2018;2018(1):513-521.
